

GUAM MEMORIAL HOSPITAL ANTIBIOGRAM
GRAM NEGATIVE ISOLATES
PERIOD: JANUARY 1, 2024- DECEMBER 31, 2024

ORGANISM	ISOL	AM	AMS	CEF	CTZ	CIP	CRO	CZ	ERT	FM	GM	MER	NN	PIP	SXT	LEV
<i>Acinetobacter baumannii</i> complex	64	NT	95	88	68	91	23	NT	NT	25	94	95	95	73	91	NT
<i>Citrobacter freundii</i>	9	NT	NT	88	38	50	56	NT	88	100	78	88	67	38	88	NT
<i>Citrobacter koseri</i>	46	NT	NT	98	98	100	96	NT	100	NT	100	100	100	29	98	NT
<i>Enterobacter aerogenes</i>	39	NT	NT	100	62	87	57	NT	100	100	100	100	100	56	97	NT
<i>Enterobacter cloacae</i> complex	97	NT	100	94	86	94	85	NT	90	67	100	93	98	78	86	NT
<i>E. coli</i>	607	37	51	96	90	61	76	65	100	100	90	100	86	40	64	NT
ESBL + = 21%	125															
<i>Klebsiella pneumoniae</i>	414	0	75	93	86	82	82	69	97	81	94	97	92	74	82	NT
ESBL+ = 13%	54															
<i>Proteus mirabilis</i>	163	88	95	100	98	98	99	73	99	0	98	99	99	94	93	NT
<i>Pseudomonas aeruginosa</i>	329	NT	NT	75	75	76	NT	NT	NT	NT	93	75	96	67	NT	NT
<i>Salmonella</i> species	7	100	NT	NT	NT	NT	100	NT	NT	NT	NT	NT	NT	NT	100	NT
<i>Serratia marcescens</i>	29	NT	NT	100	100	97	96	0	100	NT	100	100	93	96	100	NT
<i>Steno. Maltophilia</i>	60	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	88	85

ABOVE ARE EXPRESSED AS % SUSCEPTIBLE

PLEASE NOTE:


ANTIBIOTIC SELECTION SHOULD NOT BE BASED SOLELY ON THIS ANTIBIOGRAM

ADDITIONAL FACTORS THAT SHOULD BE CONSIDERED ARE:

- CLINICAL HISTORY
- TOXIC REACTIONS
- POTENTIAL FOR CONVERSION TO RESISTANCE

SUBMITTED AND APPROVED BY:


MICROBIOLOGY SUPERVISOR


LABORATORY MEDICAL DIRECTOR

DATE

5/20/25

DATE

LEGEND:

AM	AMPICILLIN
AMS	AMPICILLIN/SULBACTAM
CEF	CEFEPIME
CTZ	CEFTAZIDIME
CIP	CIPROFLOXACIN
CRO	CEFTRIAXONE
CZ	CEFAZOLIN
ERT	ERTAPENEM
FM	NITROFURANTOIN
LEV	LEVOFLOXACIN
GM	GENTAMICIN
MER	MEROPENEM
NN	TOBRAMYCIN
PIP	PIPERACILLIN
SXT	TRIMETHOPRIM/SULFAMETHOXAZOLE
*ISOL	*NUMBER OF ISOLATES
*NT	*NOT TESTED

GUAM MEMORIAL HOSPITAL ANTIBIOGRAM

GRAM POSITIVE ISOLATES

PERIOD: JANUARY 1, 2024 - DECEMBER 31, 2024

ORGANISM	ISOL	AM	CC	CIP	CZ	ERY	FM	GM	LNZ	OX	PEN	RIF	SXT	TET	VA
Staphylococcus aureus (01/01/24-7/31/24)	216	NT	95	96	100	82	NT	100	100	100	25	100	90	99	100
MRSA* (1/1/24-7/31/24)	114	NT	75	42	0	44	NT	100	100	0	0	100	88	97	100
Staphylococcus aureus (MSSA/MRSA) (08/01/24-12/31/24)	266	NT	85	79	74	73	NT	100	100	-	0	100	85	97	100
MSSA* = 73% (8/1/24-12-31/24)	194														
MRSA* = 27% (8/1/24-12/31/24)	72														
Staphylococcus epidermidis	37	NT	51	62	27	32	NT	89	100	27	0	92	78	76	100
Staphylococcus saprophyticus	8	NT	100	100	75	88	NT	100	100	75	0	100	100	100	100

*Methicillin Resistant Staphylococcus aureus

*Methicillin Resistant Staphylococcus aureus

ORGANISM	ISOL	CRO	ERY	LNZ	PEN	TET	VA
Streptococcus pneumoniae	10	100	70	100	100	60	100

ORGANISM	ISOL	AM	CIP	FM	LNZ	PEN	TET	VA
Enterococcus faecalis	199	99	86	100	97	97	37	99
Enterococcus faecium	59	2	5	-	95	0	14	8

ABOVE ARE EXPRESSED AS % SUSCEPTIBLE

PLEASE NOTE:

ANTIBIOTIC SELECTION SHOULD NOT BE BASED SOLELY ON THIS ANTIBIOGRAM

ADDITIONAL FACTORS THAT SHOULD BE CONSIDERED ARE:

- CLINICAL HISTORY
- TOXIC REACTIONS
- POTENTIAL FOR CONVERSION TO RESISTANCE

SUBMITTED AND APPROVED BY:

MICROBIOLOGY SUPERVISOR

LABORATORY MEDICAL DIRECTOR

DATE

DATE

LEGEND:

AM	AMPICILLIN
CC	CLINDAMYCIN
CIP	CIPROFLOXACIN
CRO	CEFTRIAXONE
CZ	CEFAZOLIN
ERY	ERYTHROMYCIN
FM	NITROFURANTOIN
GM	GENTAMICIN
LNZ	LINEZOLID
OX	OXACILLIN
PEN	PENICILLIN
RIF	RIFAMPIN
SXT	TRIMETHOPRIM/SULFAMETHOXAZOLE
TET	TETRACYCLINE
VA	VANCOMYCIN
*ISOL	*NUMBER OF ISOLATES
*NT	*NOT TESTED